What question did this study set out to answer?

This study aims to evaluate the real-world outcomes of a T-DM1 biosimilar in early-stage HER2-positive breast cancer patients, focusing on invasive disease-free survival and safety.

synapse

⌘+K

synapse

⌘+K

April 3, 2026Open Access

4P Real-world outcomes of a trastuzumab emtansine (T-DM1) biosimilar (Ujvira) in early-stage HER2-positive breast cancer: A single-centre retrospective study from India

Key Points

This study aims to evaluate the real-world outcomes of a T-DM1 biosimilar in early-stage HER2-positive breast cancer patients, focusing on invasive disease-free survival and safety.
Conducted as a retrospective study at a single centre in India.
Evaluated outcomes of a trastuzumab emtansine biosimilar after neoadjuvant therapy.
Assessed key metrics such as invasive disease-free survival (IDFS) and safety.
Found improvements in invasive disease-free survival (IDFS) with the T-DM1 biosimilar.
Noted acceptable safety outcomes in routine clinical practice.
Results indicate potential benefits for patients in low-resource settings.

Abstract

In the KATHERINE trial, adjuvant trastuzumab emtansine (T-DM1) significantly improved invasive disease-free survival (IDFS) in patients with residual HER2-positive breast cancer following neoadjuvant therapy. Real-world data on T-DM1 biosimilars in the post-neoadjuvant setting remain limited, particularly in low- and middle-income countries. This study evaluated IDFS and safety outcomes of a T-DM1 biosimilar in routine Indian clinical practice.

4P Real-world outcomes of a trastuzumab emtansine (T-DM1) biosimilar (Ujvira) in early-stage HER2-positive breast cancer: A single-centre retrospective study from India

Key Points

Abstract

Cite This Study

Also Consider

Also Consider